Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PX-866: Development discontinued

Oncothyreon said it does not plan to move forward with development of PX-866 for GBM after data from 33 evaluable patients with GBM at

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE